Evidence map›Paper›PMID 31669607›Full record

ArticleJournal of pharmaceutical sciences2020

Evaluation of Crystal Zenith Microtiter Plates for High-Throughput Formulation Screening.

J Alaina Floyd, Jeremy M Shaver, Alison J Gillespie, Unjy Park, Richard S Rogers, Nancy S Nightlinger, Yuko Ogata, Jeffrey J James, Bruce A Kerwin

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Journal of pharmaceutical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

J Alaina FloydJust Biotherapeutics, Inc., Seattle, Washington 98109. Electronic address: alaina.floyd@just.bio.
Jeremy M ShaverJust Biotherapeutics, Inc., Seattle, Washington 98109.
Alison J GillespieJust Biotherapeutics, Inc., Seattle, Washington 98109.
Unjy ParkJust Biotherapeutics, Inc., Seattle, Washington 98109.
Richard S RogersJust Biotherapeutics, Inc., Seattle, Washington 98109.
Nancy S NightlingerJust Biotherapeutics, Inc., Seattle, Washington 98109.
Yuko OgataJust Biotherapeutics, Inc., Seattle, Washington 98109.
Jeffrey J JamesJust Biotherapeutics, Inc., Seattle, Washington 98109.
Bruce A KerwinJust Biotherapeutics, Inc., Seattle, Washington 98109.
Just Biotherapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Formulation screening for biotherapeutics can cover a vast array of excipients and stress conditions. These studies consume quantities of limited material and, with higher concentrated therapeutics, more material is needed. Here, we evaluate the use of crystal zenith (CZ) microtiter plates in conjunction with FluoroTec-coated butyl rubber mats as a small-volume, high-throughput system for formulation stability studies. The system was studied for evaporation, edge effects, and stability with comparisons to type 1 glass and CZ vials for multiple antibodies and formulations. Evaporation was minimal at 4°C and could be reduced at elevated temperatures using sealed, mylar bags. Edge effects were not observed until 12 weeks at 40°C. The overall stability ranking as measured by the rate of change in high molecular weight and percent main peak species was comparable across both vials and plates at 4°C and 40°C out to 12 weeks. Product quality attributes as measured by the multi-attribute method were also comparable across all containers for each molecule formulation. A potential difference was measured for subvisible particle analysis, with the plates measuring lower particle counts than the vials. Overall, CZ plates are a viable alternative to traditional vials for small-volume, high-throughput formulation stability screening studies.

Indexed as

Antibodies, MonoclonalChromatography, GelChromatography, Reverse-PhaseCycloparaffinsDrug CompoundingDrug StabilityElectrophoresis, CapillaryEquipment DesignHigh-Throughput Screening AssaysImmunoglobulin Fc FragmentsMass SpectrometryMiniaturizationProtein DenaturationProtein StabilityRecombinant Fusion ProteinsTemperatureAntibodies, MonoclonalCycloparaffinsImmunoglobulin Fc FragmentsRecombinant Fusion Proteinsantibody(s)automationdevelopability screeningformulationhigh throughput technology(s)protein(s)stability

Identifiers

PMID31669607
PMCPMC6941220
OpenAlexW2981649004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.